Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

About this update from Dyadic International, Inc.

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform while supporting its broader commercialization strategy. Dyadic's C1 platform is designed to enable rapid, high-yield, and cost efficient production of recombinant proteins, vaccine antigens, monoclonal antibodies (mAbs), therapeutic proteins, enzymes, and other biologics. By accelerating strain development and efficiently secreting target proteins, C1 has the potential to address one of the industry's most significant challenges: manufacturing biologics faster, at larger scale, and at lower cost. The Company believes its fully funded emerging infectious disease preparedness initiatives, including programs targeting Ebola and hantavirus, are providing real-world demonstrations of C1's potential advantages in rapid response. These collaborations are intended to showcase how C1 may accelerate the development and production of critical biologics when speed, flexibility, scalability and manufacturing efficiency are essential. Recent Global Health Collaboration Highlights Gates Foundation-supported monoclonal antibody programs: Dyadic's Gates Foundation-supported research programs are evaluating the use of C1 for global health monoclonal antibody applications, including RSV and malaria. The Company has received the full $3.1 million Gates Foundation grant, including the final payment of $738,743 in June 2026, which is expected to fully fund the ongoing research. To date, studies have shown that C1-produced monoclonal antibodies demonstrated binding and neutralization characteristics comparable to antibodies produced using traditional CHO cell systems. In addition, the C1 platform has demonstrated higher production yields at lower projected manufacturing costs, with multiple production runs completed during the timeframe typically required for a single CHO manufacturing cycle. Coalition for Epidemic Preparedness Innovations (CEPI)/Fondazione Biotecnopolo di Siena (FBS) Program:

View stock analysis, news, and events for Dyadic International, Inc.